An Overview of SARS-CoV-2 Potential Targets, Inhibitors, and Computational Insights to Enrich the Promising Treatment Strategies

No abstract is available for this paper.

• Publication year

  2024

• Venue

  Current Microbiology

• Publication date

  2024-05-11

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.1007/s00284-024-03671-3PMID 38733424
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Natural products from Streptomyces spp. as potential inhibitors of the major factors (holoRdRp and nsp13) for SARS-CoV-2 replication: an in silico approach

  2024cited by this paper
• Computational approaches streamlining drug discovery

  2023cited by this paper
• Identification of Potential Drug Targets in Erythrocyte Invasion Pathway of Plasmodium falciparum

  2023cited by this paper
• SARS-CoV2 billion-compound docking

  2023cited by this paper
• In silico prediction of potential inhibitors for SARS-CoV-2 Omicron variant using molecular docking and dynamics simulation-based drug repurposing

  2023cited by this paper
• Docking Studies on Biomolecules from Marine Microalga Skeletonema costatum Against Hemolysin Protein of Bioluminescence Disease-Causing Vibrio harveyi

  2023cited by this paper
• Naringenin-4'-glucuronide as a new drug candidate against the COVID-19 Omicron variant: a study based on molecular docking, molecular dynamics, MM/PBSA and MM/GBSA

  2023cited by this paper
• In-silico network pharmacology study on Glycyrrhiza glabra: Analyzing the immune-boosting phytochemical properties of Siddha medicinal plant against COVID-19

  2023cited by this paper
• Repurposing of RAS-Pathway Mediated Drugs for Intestinal Inflammation Related Diseases for Treating SARS-CoV-2 Infection

  2023cited by this paper
• Identification of the Seaweed Metabolites as Potential Anti-tubercular Agents Against Human Pantothenate synthetase: An In Silico Approach

  2023cited by this paper
• Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences

  2022cited by this paper
• In silico bioprospecting of taraxerol as a main protease inhibitor of SARS-CoV-2 to develop therapy against COVID-19

  2022cited by this paper
• Integrin mediates cell entry of the SARS-CoV-2 virus independent of cellular receptor ACE2

  2022cited by this paper
• Interaction Tolerance Detection Test for Understanding the Killing Efficacy of Directional Antibiotic Combinations

  2022cited by this paper
• QSAR, homology modeling, and docking simulation on SARS-CoV-2 and pseudomonas aeruginosa inhibitors, ADMET, and molecular dynamic simulations to find a possible oral lead candidate

  2022cited by this paper
• Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19

  2022cited by this paper
• A Guide to In Silico Drug Design

  2022cited by this paper
• Nitazoxanide and COVID-19: A review

  2022cited by this paper
• SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion

  2022cited by this paper
• Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer

  2022cited by this paper
• The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules

  2022cited by this paper
• Nucleosides and emerging viruses: A new story

  2022cited by this paper
• Potential therapeutic options for COVID-19: an update on current evidence

  2022cited by this paper
• Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study

  2021cited by this paper
• Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

  2021cited by this paper
• Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial

  2021cited by this paper
• In silico approach for identification of natural compounds as potential COVID 19 main protease (Mpro) inhibitors

  2021cited by this paper
• Transcription factor NF-κB as target for SARS-CoV-2 drug discovery efforts using inflammation-based QSAR screening model

  2021cited by this paper
• Drug repurposing for COVID-19: Approaches, challenges and promising candidates

  2021cited by this paper
• Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial

  2021cited by this paper
• Roles of existing drug and drug targets for COVID-19 management

  2021cited by this paper
• How SARS-CoV-2 makes the cut

  2021cited by this paper
• A critical overview of computational approaches employed for COVID-19 drug discovery

  2021cited by this paper
• Recent advances in developing small-molecule inhibitors against SARS-CoV-2

  2021cited by this paper
• Collagen- and hyaluronic acid-based hydrogels and their biomedical applications.

  2021cited by this paper
• SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response

  2021cited by this paper
• Proteolytic activation of SARS‐CoV‐2 spike protein

  2021cited by this paper
• Mechanisms of SARS-CoV-2 entry into cells

  2021cited by this paper
• Niclosamide—A promising treatment for COVID‐19

  2021cited by this paper
• Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets

  2021cited by this paper
• Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

  2021cited by this paper
• Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity

  2021cited by this paper
• Intermediate filaments.

  2021cited by this paper
• Current understanding of the influence of environmental factors on SARS-CoV-2 transmission, persistence, and infectivity

  2021cited by this paper
• COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection

  2021cited by this paper
• Impact of the coronavirus (COVID-19) pandemic on scientific research and implications for clinical academic training – A review

  2021cited by this paper
• In silico Screening of Natural Compounds as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike RBD: Targets for COVID-19

  2021cited by this paper
• The efficacy of different seed priming agents for promoting sorghum germination under salt stress

  2021cited by this paper
• Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics

  2021cited by this paper
• SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19

  2021cited by this paper
• Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents

  2021cited by this paper
• Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies

  2021cited by this paper
• Mapping major SARS-CoV-2 drug targets and assessment of druggability using computational fragment screening: Identification of an allosteric small-molecule binding site on the Nsp13 helicase

  2021cited by this paper
• Identification of high affinity and low molecular alternatives of boceprevir against SARS-CoV-2 main protease: A virtual screening approach

  2021cited by this paper
• Deep learning techniques have significantly impacted protein structure prediction and protein design.

  2021cited by this paper
• NSP16 2′-O-MTase in Coronavirus Pathogenesis: Possible Prevention and Treatments Strategies

  2021cited by this paper
• Reducing SARS-CoV-2 pathological protein activity with small molecules

  2021cited by this paper
• Coronavirus genomic nsp14‐ExoN, structure, role, mechanism, and potential application as a drug target

  2021cited by this paper
• Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

  2021cited by this paper
• Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19

  2021cited by this paper
• The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets

  2021cited by this paper
• Is carbonic anhydrase inhibition useful as a complementary therapy of Covid-19 infection?

  2021cited by this paper
• Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment

  2021influential reference
• Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy

  2021cited by this paper
• Analysis of non-structural proteins, NSPs of SARS-CoV-2 as targets for computational drug designing

  2020cited by this paper
• Potential detrimental role of soluble ACE2 in severe COVID‐19 comorbid patients

  2020cited by this paper
• Natural load-bearing protein materials

  2020cited by this paper
• Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients

  2020influential reference
• An Investigation of the Expression of 2019 Novel Coronavirus Cell Receptor Gene ACE2 in a Wide Variety of Human Tissues

  2020cited by this paper
• Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors

  2020cited by this paper
• The RNA-Dependent RNA Polymerase NIb of Potyviruses Plays Multifunctional, Contrasting Roles during Viral Infection

  2020cited by this paper
• The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

  2020cited by this paper
• SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

  2020cited by this paper
• SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development

  2020cited by this paper
• Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses

  2020cited by this paper
• A Review on Applications of Computational Methods in Drug Screening and Design

  2020cited by this paper
• Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

  2020cited by this paper
• Genotype and phenotype of COVID-19: Their roles in pathogenesis

  2020cited by this paper
• The impact of the SARS‐CoV‐2 outbreak on the safety and availability of blood transfusions in Italy

  2020cited by this paper
• Ten quick tips for homology modeling of high-resolution protein 3D structures

  2020cited by this paper
• SARS‐CoV‐2 spike protein favors ACE2 from Bovidae and Cricetidae

  2020cited by this paper
• Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

  2020cited by this paper
• Coronavirus membrane fusion mechanism offers a potential target for antiviral development

  2020cited by this paper
• The socio-economic implications of the coronavirus pandemic (COVID-19): A review

  2020cited by this paper
• Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant

  2020cited by this paper
• A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia

  2020cited by this paper
• Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues

  2020cited by this paper
• Biochemical characterization of SARS-CoV-2 nucleocapsid protein

  2020cited by this paper
• Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome

  2020cited by this paper
• SARS-CoV-2 RNA polymerase as target for antiviral therapy

  2020cited by this paper
• Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review

  2020cited by this paper
• Identification of novel mutations in RNA-dependent RNA polymerases of SARS-CoV-2 and their implications on its protein structure

  2020cited by this paper
• SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc

  2020cited by this paper
• The urgent need for integrated science to fight COVID-19 pandemic and beyond

  2020cited by this paper
• A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic

  2020influential reference
• Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2

  2020influential reference
• Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

  2020cited by this paper
• Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19

  2020influential reference
• Biofilm Matrixome: Extracellular Components in Structured Microbial Communities.

  2020cited by this paper
• A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID‐19

  2020cited by this paper

• Discovery of a 2'-α-Fluoro-2'-β-C-(fluoromethyl) Purine Nucleotide Prodrug as a Potential Oral Anti-SARS-CoV-2 Agent.

  2025cites this paper
• Nucleoside antiviral agents with atypical structures and new targets.

  2025cites this paper
• Identification of new candidate molecules against SARS-CoV-2 through docking studies

  2025cites this paper
• ATPase-dependent duplex nucleic acid unwinding by SARS-CoV-2 nsP13 relies on facile binding and translocation along single-stranded nucleic acid

  2025cites this paper
• Studying the Role of Impulsive Antiviral Therapy for SARS‐CoV‐2 Treatment Using a Delay Induced Mathematical Model

  2025cites this paper